The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2020 | CLL: the GREEN study
Véronique Leblond, MD, Hematology at Pitié Salpêtrière Hospital, Paris, France, explores the results of a subgroup analysis of the GREEN study (NCT01905943), evaluating obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
